{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:54:50Z","timestamp":1792979690729,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108328","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:37:58Z","timestamp":1782625078000},"page":"108328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting androgen receptor transcriptionally represses VCP and enhances the efficacy of oncolytic-immunotherapy in hepatocellular carcinoma"],"prefix":"10.1016","volume":"230","author":[{"given":"Yang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1921-6648","authenticated-orcid":false,"given":"Peixu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pincheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weishuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2026.108328_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.phrs.2026.108328_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108328_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.phrs.2026.108328_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-025-01739-6","article-title":"Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy","volume":"18","author":"Dai","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"13","key":"10.1016\/j.phrs.2026.108328_bib5","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2002.10.018","article-title":"Molecular biology of the androgen receptor","volume":"20","author":"Gelmann","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.phrs.2026.108328_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213768","article-title":"Constitutively active androgen receptor in hepatocellular carcinoma","volume":"23","author":"Montgomery","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2026.108328_bib7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.molonc.2012.06.005","article-title":"Activation of androgen receptor induces ID1 and promotes hepatocellular carcinoma cell migration and invasion","volume":"6","author":"Ao","year":"2012","journal-title":"Mol. Oncol."},{"issue":"21","key":"10.1016\/j.phrs.2026.108328_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215417","article-title":"Androgen receptor signaling in prostate cancer and therapeutic strategies","volume":"13","author":"Jacob","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.phrs.2026.108328_bib9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40261-021-01063-0","article-title":"Efficacy and safety results from a phase 2, randomized, double-blind study of enzalutamide versus placebo in advanced hepatocellular carcinoma","volume":"41","author":"Ryoo","year":"2021","journal-title":"Clin. Drug. Investig."},{"issue":"6","key":"10.1016\/j.phrs.2026.108328_bib10","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/hep.29715","article-title":"Significance and mechanism of androgen receptor overexpression and androgen receptor\/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma","volume":"67","author":"Zhang","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.phrs.2026.108328_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/biology10050384","article-title":"The unfolded protein response: an overview","volume":"10","author":"Read","year":"2021","journal-title":"Biology"},{"issue":"5","key":"10.1016\/j.phrs.2026.108328_bib12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.molcel.2009.08.021","article-title":"Fine-tuning of the unfolded protein response: assembling the IRE1alpha interactome","volume":"35","author":"Hetz","year":"2009","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.phrs.2026.108328_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrm3270","article-title":"The unfolded protein response: controlling cell fate decisions under ER stress and beyond","volume":"13","author":"Hetz","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108328_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108328_bib15","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s13277-012-0504-2","article-title":"Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy","volume":"33","author":"Kohles","year":"2012","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108328_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/cdd.2013.75","article-title":"Molecular mechanisms of ATP secretion during immunogenic cell death","volume":"21","author":"Martins","year":"2014","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.phrs.2026.108328_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108328_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040547","article-title":"Combination therapy of novel oncolytic adenovirus with anti-PD1 resulted in enhanced anti-cancer effect in syngeneic immunocompetent melanoma mouse model","volume":"13","author":"Garofalo","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.phrs.2026.108328_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2416558","article-title":"Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer","volume":"13","author":"Wang","year":"2024","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108328_bib20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12967-025-06267-y","article-title":"Histidine metabolism drives liver cancer progression via immune microenvironment modulation through metabolic reprogramming","volume":"23","author":"Liu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108328_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102404","article-title":"Estrogen inhibits hepatocellular carcinoma progression dependent on HOXA11-AS\/HOXA11","volume":"57","author":"Zhou","year":"2025","journal-title":"Transl. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108328_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101664","article-title":"Protocol to isolate and analyze mouse bone marrow derived dendritic cells (BMDC)","volume":"3","author":"Sauter","year":"2022","journal-title":"STAR Protoc."},{"key":"10.1016\/j.phrs.2026.108328_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.actbio.2025.01.029","article-title":"Manganese dioxide-based in situ vaccine boosts antitumor immunity via simultaneous activation of immunogenic cell death and the STING pathway","volume":"194","author":"Peng","year":"2025","journal-title":"Acta Biomater."},{"issue":"17","key":"10.1016\/j.phrs.2026.108328_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202411879","article-title":"Enhanced tumor ablation and immune activation via irreversible electroporation and functionalized vermiculite nanosheets","volume":"21","author":"Li","year":"2025","journal-title":"Small"},{"issue":"4","key":"10.1016\/j.phrs.2026.108328_bib25","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1096\/fj.201903045RR","article-title":"Olaparib and enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p\/BRCA1 signaling","volume":"34","author":"Zhao","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2026.108328_bib26","article-title":"Distinct roles in phagocytosis of the early and late increases of cell surface calreticulin induced by oxaliplatin","volume":"29","author":"Matsusaka","year":"2022","journal-title":"Biochem. Biophys. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2026.108328_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2026.108328_bib28","first-page":"363","article-title":"Cancer treatment and survivorship statistics","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.phrs.2026.108328_bib29","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/jcb.20593","article-title":"Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility","volume":"98","author":"Marcelli","year":"2006","journal-title":"J. Cell. Biochem."},{"issue":"7","key":"10.1016\/j.phrs.2026.108328_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2026.108328_bib31","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1158\/0008-5472.CAN-15-1142","article-title":"Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis","volume":"76","author":"Fucikova","year":"2016","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108328_bib32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/dna.2023.0368","article-title":"Oncolytic therapy of solid tumors by modified vesicular stomatitis virus","volume":"43","author":"Gao","year":"2024","journal-title":"DNA Cell Biol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108328_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32110627","article-title":"Vesicular stomatitis virus-based oncolytic virotherapy: recent progress and emerging trends","volume":"32","author":"Catacalos-Goad","year":"2025","journal-title":"Curr. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108328_bib34","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1182\/blood-2007-01-065573","article-title":"Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene","volume":"110","author":"Goel","year":"2007","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.phrs.2026.108328_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202206889","article-title":"IL-1beta is an androgen-responsive target in macrophages for immunotherapy of prostate cancer","volume":"10","author":"Wang","year":"2023","journal-title":"Adv. Sci."},{"issue":"26","key":"10.1016\/j.phrs.2026.108328_bib36","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1200\/JCO.23.00433","article-title":"Targeting the androgen signaling axis in prostate cancer","volume":"41","author":"Dai","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108328_bib37","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.phrs.2026.108328_bib38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108328_bib39","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.phrs.2026.108328_bib40","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1080\/15548627.2015.1082022","article-title":"Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer","volume":"11","author":"Ladoire","year":"2015","journal-title":"Autophagy"},{"issue":"7637","key":"10.1016\/j.phrs.2026.108328_bib41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2026.108328_bib42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1152\/physrev.00043.2006","article-title":"Physiology and pathophysiology of purinergic neurotransmission","volume":"87","author":"Burnstock","year":"2007","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2026.108328_bib43","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.trecan.2016.03.007","article-title":"Endoplasmic reticulum stress and the hallmarks of cancer","volume":"2","author":"Urra","year":"2016","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2026.108328_bib44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108328_bib45","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2026.108328_bib46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","article-title":"Endoplasmic reticulum stress signals in the tumour and its microenvironment","volume":"21","author":"Chen","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2026.108328_bib47","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nchembio.1313","article-title":"Covalent and allosteric inhibitors of the ATPase VCP\/p97 induce cancer cell death","volume":"9","author":"Magnaghi","year":"2013","journal-title":"Nat. Chem. Biol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108328_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25115633","article-title":"Valosin-containing protein (VCP): a review of its diverse molecular functions and clinical phenotypes","volume":"25","author":"Pontifex","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.phrs.2026.108328_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2017.72","article-title":"Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers","volume":"6","author":"Avril","year":"2017","journal-title":"Oncogenesis"},{"issue":"7686","key":"10.1016\/j.phrs.2026.108328_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.phrs.2026.108328_bib51","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","article-title":"Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy","volume":"184","author":"Koikawa","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.phrs.2026.108328_bib52","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","article-title":"ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis","volume":"37","author":"Liu","year":"2020","journal-title":"Cancer Cell"},{"issue":"404","key":"10.1016\/j.phrs.2026.108328_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7996","article-title":"Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma","volume":"9","author":"Zhang","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108328_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176913","article-title":"Immunogenic cell death-based oncolytic virus therapy: a sharp sword of tumor immunotherapy","volume":"981","author":"Zhang","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108328_bib55","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108328_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113318","article-title":"Targeting VCP potentiates immune checkpoint therapy for colorectal cancer","volume":"42","author":"Wang","year":"2023","journal-title":"Cell Rep."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:01:33Z","timestamp":1785074493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":56,"alternative-id":["S1043661826002434"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108328","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting androgen receptor transcriptionally represses VCP and enhances the efficacy of oncolytic-immunotherapy in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108328"}}